September 9th 2025
Sandoz received FDA approval for its biosimilar Enzeevu (aflibercept-abzv) on August 12, 2024. It has the same dosage form, route of administration, and presentation as the reference medicine, Eylea, from Regeneron.
Ranibizumab biosimilar achieves similar results in patients with polypoidal choroidal vasculopathy
September 27th 2022Anti-VEGF biosimilars may offer a therapeutic alternative to the original biologic because they have the ability to lower the overall therapeutic cost in the management of varied chorioretinal disorders.
Read More